The active pharmaceutical ingredient described in this specification is Cefpirome Sulfate (sterile) Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable. The product is assigned two manufacturing process grades: an injection-grade powder with a laser-diffraction D90 limit of 15 µm, and an oral/granule-grade powder with a D90 limit of 45 µm. Both grades are released against the same sterility, bacterial endotoxin, and chemical purity specifications, but differ in particle size, bulk density, and powder flow characteristics. The active moiety is a fourth-generation cephalosporin with the empirical formula C₂₂H₂₂N₆O₅S₂·H₂SO₄, CAS 98753-19-6. Unlike cefotaxime, ceftriaxone, and ceftazidime, the molecule carries a 2,3-cyclopentenopyridinium substituent at C-3, which creates a permanent quaternary ammonium charge. This structural feature produces a zwitterionic molecule with improved aqueous solubility and altered outer-membrane penetration in many Gram-negative pathogens, but also limits passive intestinal permeability. The sulfate counterion produces a reconstituted injection solution pH of 1.6–2.1 at 100 mg/mL, a parameter that controls both drug stability and infusion compatibility. The sterile API is supplied as a preservative-free powder for single-dose parenteral administration after aseptic filling into depyrogenated glass vials. For tablet, capsule, and granule formats, the sterile API is used where systemic oral bioavailability is not the primary objective, or where the dossier includes absorption-enhancement and enteric-protection data. Release testing is anchored to Ph. Eur. 2.6.1 sterility, USP <71> sterility, USP <788> particulate matter, and ICH Q3D elemental impurities. The product is not an excipient premix and must be handled as a beta-lactam active pharmaceutical ingredient with sensitization control and cross-contamination requirements.

What Limits Oral Systemic Use of Cefpirome Sulfate?

The quaternary ammonium centre at C-3 limits oral absorption. In Caco-2 permeability models, zwitterionic cephalosporins of this class frequently show apparent permeability coefficients below 1.0 × 10⁻⁶ cm/s, which is lower than the threshold usually required for consistent systemic oral bioavailability. Published human pharmacokinetic data for oral cefpirome sulfate is limited; therefore, oral tablet or capsule formulations should not be assumed systemically bioequivalent to intravenous injection without a dedicated bioavailability study. Oral solid dosage forms containing the sterile API are accordingly developed for local gastrointestinal exposure, non-systemic protocols, or modified-release systems in which release and absorption are explicitly characterised. In oral granule production, the acidic sulfate salt and the beta-lactam ring impose processing boundaries. Wet granulation in a high-shear granulator is conducted with impeller tip speed between 5 m/s and 10 m/s and water addition below 0.8 g/min/kg of dry mass to limit local heating and hydrolytic degradation. Granulation end point is determined by torque increase of 8–12% above the dry-mixing baseline, because fixed-time control produces batch-to-batch water variance. Fluid-bed drying is performed with inlet air below 45 °C and final loss on drying below 1.5% m/m. Granules intended for sachet or capsule filling are sieved through a 1.4 mm mesh; the retained fraction above 1.4 mm is controlled below 5% for rapid dispersion.

Differences from other cephalosporins are summarised in the following comparative matrix. The table is based on structural and microbiological characteristics, not on clinical superiority.

Injectable manufacturing uses aseptic powder filling instead of terminal sterilisation. Depyrogenation of Type II glass vials is performed in a hot-air tunnel at 250 °C for 30 min; rubber stoppers are steam-sterilised at 121 °C for 30 min. The sterile API is passed through a 425 µm stainless steel sieve to break agglomerates before entering the filling hopper. A 1 g dose reconstituted in 10 mL water for injection wets in less than 90 s under gentle swirling. Vigorous shaking is avoided because it generates foam and increases subvisible particle counts. Reconstituted solutions are evaluated by light obscuration using USP <788> and Ph. Eur. 2.9.19; the acceptance criteria are 6000 particles ≥10 µm and 600 particles ≥25 µm per container. For intravenous infusion, the solution is usually diluted to 10–20 mg/mL in 0.9% sodium chloride injection or 5% dextrose injection. Lactated Ringer solution is generally avoided because its alkaline pH accelerates beta-lactam hydrolysis. Transfer lines are equipped with 0.2 µm polyethersulfone filters; nylon or aliphatic polyamide membranes are not used because the acidic solution can extract cationic contaminants. Terminal steam sterilisation at 121 °C is incompatible with the beta-lactam ring and is excluded from the process. The finishing route uses aseptic crystallization with terminal sterile filtration and vacuum drying at product temperature not exceeding 30 °C. Endotoxin is maintained below 0.10 EU/mg. A production bottleneck is moisture uptake when relative humidity exceeds 30% during powder transfer; this is controlled by isolator air handling and pre-dried compressed air. In clinical use, susceptibility interpretation follows CLSI M100 and EUCAST clinical breakpoint tables. The injectable form is not active against methicillin-resistant Staphylococcus aureus, Bacteroides fragilis, or Stenotrophomonas maltophilia.

Sterile API Release Specifications and Analytical Methods

The batch release panel includes chromatographic purity, water content, sterility, bacterial endotoxin, particulate matter, residual solvents, elemental impurities, and pH. The HPLC assay uses a C18 column with UV detection at 254 nm, flow rate 1.0 mL/min, and a phosphate buffer–acetonitrile mobile phase. The following limits are applied at release.

In tablet/capsule processing, the sterile API exhibits low bulk density and poor flow. Typical bulk density of the sterile milled powder ranges from 0.28 g/mL to 0.35 g/mL, with a Carr index above 30. Roller compaction is used to densify the powder before encapsulation or tableting. Compaction at roll pressure 4–6 kN/cm and a 1.0 mm screen produces granules with bulk density 0.55–0.65 g/mL, improving flow and reducing segregation. The granulated material is compressed on a rotary tablet press at 30–60 rpm with compression force 8–12 kN; tablet hardness is monitored because excessive force can increase disintegration time and accelerate moisture sensitivity. For capsules, the granulate is filled under nitrogen purge to protect the aminothiazole ring from oxidative discoloration. Film coating with a methacrylic acid copolymer dispersion is applied to protect the active substance from gastric acid and to reduce the local acid load of the sulfate salt. Dissolution testing is performed by USP <711> Apparatus II at 50 rpm in 900 mL of pH 6.8 phosphate buffer; a typical acceptance criterion is not less than 75% release at 45 min. Oral solid formulations are packaged in aluminium-aluminium blister packs with a silica gel canister because moisture uptake above 1.5% water can initiate hydrolytic degradation and reduce assay below release limits. Compared with oral third-generation agents such as cefixime and cefdinir, cefpirome sulfate does not have a clinically established oral prodrug or absorption pathway in major markets. Cefuroxime axetil relies on an ester prodrug to achieve oral bioavailability; cefpirome sulfate lacks a corresponding marketed prodrug entity.

When Terminal Sterilization Is Replaced by Aseptic Crystallization

Because cefpirome sulfate is heat-labile, sterile grade manufacturing relies on aseptic crystallization and sterile filtration of all process streams. A thermostated crystallizer is used with a cooling ramp of 0.5 °C/min from supersaturation to 5 °C. Acetone is added as an antisolvent at 2.0 mL/min per litre of batch volume; faster addition creates needle-like crystals with poor filtration and higher subvisible particle counts after reconstitution. The crystal suspension is filtered through a 0.22 µm sterilizing-grade membrane, and the retained solid is vacuum-dried at 25 °C for 12 h. Injection-grade material is then jet-milled with nitrogen at 0.7 MPa and classifier speed 6000 rpm to reach D90 15 µm. The milling operation generates electrostatic charge; in-line ionizing bars are required to prevent powder accumulation on stainless steel contact parts. Environmental monitoring follows ISO 14698-1, with active air limits of ≤1 CFU/m³ and settle plates of ≤5 CFU/4 h in the critical filling zone. Sterile filter integrity is tested before and after use; any loss of integrity requires batch rejection. Batch-to-batch differences in crystal habit are controlled by the antisolvent flow rate and cooling profile; excursions shift the D90 and can prolong reconstitution time.

Storage of the sterile API is maintained at 2–8 °C in sealed aluminium-foil bags under nitrogen. The powder is hygroscopic; open handling should not exceed 30 min at 25 °C/60% RH without re-drying. The API is incompatible with strong oxidising agents, strong bases, primary amines, and moisture-releasing excipients such as hydrous lactose. After reconstitution, the solution is used within 6 h at 25 °C or stored at 2–8 °C for not more than 24 h, unless a validated extended stability data set is available. These limits apply specifically to the sulfate salt and are not interchangeable with cefepime hydrochloride or ceftazidime pentahydrate. The sterile API is not compatible with natural rubber latex stoppers; fluoropolymer-coated closures are preferred for long-term contact.